trial · primary record
Lunresertib
Advanced Solid Tumor
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 464 |
| Primary completion | 2028-06 |
| Primary endpoint | Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors |
| Registry ID | NCT04855656 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:27.156Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04855656
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.